pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$RAPPRapport Therapeutics, Inc.

$RAPP23.76-4.27%
Boston, MA, USupdated 17h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
RAP-219
Bipolar I Disorder

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 5, 2026
earnings
$RAPP23.76-4.27%
13d ago
Rapport Therapeutics, Inc. earnings
Rapport Therapeutics, Inc.
→
view all catalysts →

Active trials

  • phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizuresrecruitingn=312
  • phase2Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disordercompletedn=253
  • phase3Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1recruitingn=333
  • phase2Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsycompletedn=30
  • phase2A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizuresrecruitingn=30
🐶 Hiring Signal
14 open roles at Rapport Therapeutics, Inc. →

Where Rapport Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaCNS / Neuroscience 14
departmentClinical 5IT & Engineering 2Biostatistics / Data 2Medical Affairs 1Regulatory 1Supply Chain 1

News

  • Steady stream of crossover rounds stock biotech's IPO pipeline
    Biotech crossover rounds could top $4.22 billion across about 28 rounds this year, PitchBook forecasts.
    biospace · 2mo ago
identifiers
ticker
$RAPP
SEC CIK
0002012593
country
US
source
sec_tickers
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 57m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?